Objectives

After participating in this educational activity, attendees should be able to:
1. Understand how a 30 years old  test, CA-125 has become a mayor opportunity for targeted therapy 
2. Triaging Pelvic Masses and Choice of First line Therapy for Ovarian Cancer
3. Optimal Use of Biomarkers BRCA and MMR IHC

Faculty

Richard T. Penson, MRCP, MD
Associate Professor of Medicine
Harvard Medical School, Boston, USA
 

Faculty Disclosure

The design and content of Baystate Continuing Interprofessional Education ( CE ) activities support quality improvement in healthcare and provide fair and balanced views of therapeutic options.  All relevant financial relationships are mitigated prior to the educational activity.

Dr. Penson is a consultant for AbbVie, AstraZeneca, Cancer Panels, Care4ward (Unpaid), Eisai, Genentech, Intellisphere, Merck & Co., Sutro Biopharma, Tesaro Inc., Vascular Biogenics Ltd, WebMD, receives grant research support from Array Bio pharma Inc., AstraZeneca., Eisai Inc., Genentech, Inc., Regeneron, Sanofi-Aventis US LLC, Tesaro Inc., Vascular Biogenics Ltd., and receives royalties from BMJ Publishing, UptoDate, Elsevier Ltd., Wolters Kluwer Health, Wiley Blackwell    

None of planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services consumed by or used on patients.